Wilkins, Justin J.
Vugmeyster, Yulia
Dussault, Isabelle
Girard, Pascal
Khandelwal, Akash
Clinical trials referenced in this document:
Documents that mention this clinical trial
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
https://doi.org/10.1007/s11523-021-00809-2
375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2020-sitc2020.0375
116 Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies
https://doi.org/10.1136/ijgc-2021-esgo.8
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types
https://doi.org/10.1007/s12325-019-01018-0
P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer
https://doi.org/10.1136/ijgc-2019-esgo.100
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2022-004601
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
https://doi.org/10.1136/jitc-2020-000564
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
https://doi.org/10.1136/jitc-2020-001395
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2021-sitc2021.006
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-008480
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
https://doi.org/10.1136/jitc-2020-000664
Documents that mention this clinical trial
Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types
https://doi.org/10.1007/s12325-019-01018-0
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer (Results)
https://doi.org/10.1136/jitc-2020-000564
Funding for this research was provided by:
Merck Healthcare KGaA
GlaxoSmithKline
Article History
Received: 30 April 2019
First Online: 5 July 2019